5 cell and gene therapies have already been approved by the FDA at LONZA's Houston plant.
Alberto Santagostino, SVP, Head of Cell and Gene Technologies at Lonza, commented: "The two new approvals represent an important milestone for bluebird bio and the patients who can now benefit from these therapies. The successful approvals reflect our colleagues’ dedication to supporting our customers in bringing these cell and gene therapies to market. Opened less than five years ago, our Houston site is now manufacturing three commercial cell and gene therapies. We look forward to supporting more customers on their path to commercialization as we continue on our journey towards wider cell and gene therapy adoption."
Reg
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection, page-73
-
- There are more pages in this discussion • 203 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |